
Basecamp Research said on Wednesday it has raised $140 million in a Series C funding round that valued the AI-based drug developer at $800 million.
C3.
| Revenue (TTM) | $232.38M |
| Gross Profit (TTM) | $67.61M |
| EBITDA | $-447.08M |
| Operating Margin | -186.30% |
| Return on Equity | -59.80% |
| Return on Assets | -31.20% |
| Revenue/Share (TTM) | $1.60 |
| Book Value | $4.35 |
| Price-to-Book | 2.51 |
| Price-to-Sales (TTM) | 7.37 |
| EV/Revenue | 4.737 |
| EV/EBITDA | -2.30 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -25.50% |
| Shares Outstanding | $157.28M |
| Float | $144.21M |
| % Insiders | 8.13% |
| % Institutions | 64.07% |
Volatility is currently expanding

Basecamp Research said on Wednesday it has raised $140 million in a Series C funding round that valued the AI-based drug developer at $800 million.

Recently, Zacks.com users have been paying close attention to C3.ai (AI). This makes it worthwhile to examine what the stock has in store.

Speculative software names are absorbing most of the day's selling on Wednesday midday, even as the broader U.S. market drifts higher. The iShares Expanded Tech-Software Sector ETF (CBOE:IGV) sits at $105.36, down 0.

Shares of C3.ai (NYSE:AI | AI Price Prediction) are climbing Monday afternoon as a sharp rebound in beaten-down enterprise artificial intelligence (AI) software names sweeps across the group. C3.ai stock is up 7% to $11.

'The Big Money Show' panel discusses AI fears and says they are 'designed to scare' the public, according to former White House AI czar David Sacks. FOX Business' Dagen McDowell argues that the media had responsibility in this AI fear.

Although the revenue and EPS for C3.ai (AI) give a sense of how its business performed in the quarter ended July 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks.com users have recently been watching C3.ai (AI) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

C3.ai is upgraded to Buy, citing early signs of recovery under founder Thomas Siebel's renewed leadership. Q1 bookings surged over 70% sequentially, reflecting successful sales team restructuring and renewed customer momentum. AI's holistic enterprise AI stack and $650M cash position provide strategic flexibility and operational runway.

C3.ai, Inc. is undergoing a turnaround led by returning CEO Thomas Siebel, focusing on execution and restructuring sales strategies. Q1 2027 showed progress: bookings up 73% QoQ, federal bookings up 138% YoY, and positive free cash flow of $2.1 million. Non-GAAP gross margin improved to 50% and operating expenses fell sharply after a 40% headcount reduction, but revenue remains down YoY.

C3.ai, Inc. (AI) Q1 2027 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AI and any ticker you trade — then tracks every position and per-strategy win rate.